Research peptide blend supplied in Australia by Pulse Biolabs for laboratory use. Available in TB-500 10mg + BPC-157 10mg + GHK-Cu 50mg + KPV 10mg.
Catalogue blend
One vial, more than one compound. Each component has its own research note.
Labelled composition: TB-500 10 mg, BPC-157 10 mg, GHK-Cu 50 mg and KPV 10 mg in one vial. No published study of this blend was identified; each component’s evidence is separate. Combining compounds in one vial does not add their studies together.
TB-500 — Pulse Research // 013 TB-500 is the synthetic form of thymosin β4, a 43-amino-acid protein present in most human cells that controls the actin scaffolding a cell uses to move and change shape.
BPC-157 — Pulse Research // 009 BPC-157 is a synthetic fifteen-amino-acid peptide described by its developers as a fragment of a protective protein in human gastric juice.
KPV — Pulse Research // 026 KPV is a three-amino-acid fragment (lysine-proline-valine) from the end of alpha-melanocyte-stimulating hormone, a hormone involved in both pigmentation and inflammatory signalling.
Supplied as lyophilised (freeze-dried) powder in a single sealed vial containing more than one peptide. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Because the components differ in stability, solvent choice and handling after reconstitution are a matter for the laboratory’s own procedures and are not specified here.
Status and limitations
The statuses below are the components’. A finished mixture is subject both to any restriction on its components and to the requirements that apply to it as a product; neither is settled by adding the components’ statuses together.
TB-500: TB-500 / thymosin β4 is not an approved medicine in Australia. It is prohibited at all times in sport under category S2 of the 2026 WADA Prohibited List.
BPC-157: In Australia BPC-157 is a Schedule 4 (prescription only) substance under the Poisons Standard, and listed in Appendix D (clause 5), which the states and territories apply through their own poisons legislation to restrict possession without authority; the entries took effect on 1 June 2024 and remain in the June 2026 instrument. It is not an approved medicine in Australia, and no approval elsewhere was identified. BPC-157 is named under S0 (non-approved substances) on the WADA 2026 Prohibited List, prohibited at all times.
GHK-Cu: GHK-Cu is not an approved medicine in Australia; the TGA names it among unapproved peptide products in its advisory on importing, compounding and supplying such products. No regulator-approved GHK-Cu medicine was identified for this note; the peptide appears in cosmetic products, which are regulated differently from medicines.
KPV: KPV is not an approved medicine in Australia and is not listed in the Poisons Standard (June 2026). No overseas regulator has approved KPV as a medicine.
All products supplied by Pulse Biolabs are intended strictly for laboratory and research use. They are not medicines, are not for human or veterinary consumption, and are not supplied for the diagnosis, treatment, cure or prevention of any condition. No therapeutic claims are made.